• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development for new cancer vaccine against heterogenicity and HLA-loss of tumor

Research Project

Project/Area Number 16591297
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionThe University of Tokyo

Principal Investigator

TSUNODA Takuya  The University of Tokyo, Institute of Medical Science, Advanced Clinical Research Center, Department of Surgery and Bioengineering, Associate Professor, 医科学研究所, 特任助教授 (30275359)

Co-Investigator(Kenkyū-buntansha) TAHARA Hideaki  The University of Tokyo, Institute of Medical Science, Advanced Clinical Research Center, Department of Surgery and Bioengineering, Professor, 医科学研究所, 教授 (70322071)
TAKAYAMA Takuya  The University of Tokyo, Institute of Medical Science, Advanced Clinical Research Center, Department of Surgery and Bioengineering, Associate Professor, 医科学研究所, 講師 (10332579)
Project Period (FY) 2004 – 2005
Project Status Completed (Fiscal Year 2005)
Budget Amount *help
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 2004: ¥1,800,000 (Direct Cost: ¥1,800,000)
KeywordsEpitope peptide / Tumor heterogenicity / HLA Loss / CTL / Cancer vaccine / ペプチド / 細胞障害性T細胞 / 免疫療法 / がんワクチン療法
Research Abstract

Recently, cancer vaccine using epitope peptides was performed all over the world. Epitope peptides induced the strong cytotoxic T lymphocytes (CTL) in cancer patients, therefore clinical trials of cancer vaccine were performed. However, the outcome of clinical trial has not so excellent. One of the reasons was due to the heterogenicity and HLA-loss of the tumor. To overcome these problems, we focused on the tumor angiogenesis and examined the immunogenicity for tumor-angiogenesis related targets.
In this study, we have determined the immunogenicity from these targets. We have determined epitope peptides restricted to HLA-A^*2402 which was the most common in Japanese. These findings may suggest that tumor-angiogenesis related targets are excellent targets to improve the clinical efficacy of cancer vaccine.

Report

(3 results)
  • 2005 Annual Research Report   Final Research Report Summary
  • 2004 Annual Research Report
  • Research Products

    (14 results)

All 2005 2004

All Journal Article (14 results)

  • [Journal Article] Dendritic cell might be one of key factors for eliciting antitumor effect by chemo-immunotherapy in vivo.2005

    • Author(s)
      Mushiake H, Tsunoda T, et al.
    • Journal Title

      Cancer Immunology Immunotherpy 54

      Pages: 120-128

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Rationale for anti-angiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2 (VEGFR2).2005

    • Author(s)
      Wada S, Tsunoda T, et al.
    • Journal Title

      Cancer Research 65

      Pages: 4939-4946

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Identification of Immunoglobulin superfamily 11 (IGSF11) as a Novel Target for Cancer Immunotherapy of Gastro-intestinal and Hepatocellular Carcinomas.2005

    • Author(s)
      Watanabe T, Suda T, Tsunoda T, et al.
    • Journal Title

      Cancer Sci 96

      Pages: 498-506

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Dendritic cell might be one of key factors for eliciting antitumor effect by chemo-immunotherapy in vivo.2005

    • Author(s)
      Mushiake H, Tsunoda T, et al.
    • Journal Title

      Cancer Immunol Immunother 54

      Pages: 120-128

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Rationale for anti-angiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2 (VEGFR2).2005

    • Author(s)
      Wada S, Tsunoda T, et al.
    • Journal Title

      Cancer Res 65

      Pages: 4939-4946

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Identification of Immunoglobulin superfamily 11 (IGSF11) as a Novel Target for Cancer Immunotherapy of Gastro-intestinal and Hepatocellular Carcinomas.2005

    • Author(s)
      Takeshi Watanabe, Takako Suda, Takuya Tsunoda, et al.
    • Journal Title

      Cancer Sci 96

      Pages: 498-506

    • Related Report
      2005 Annual Research Report
  • [Journal Article] Rationale for anti-angiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2 (VEGFR2).2005

    • Author(s)
      Satoshi Wada, Takuya Tsunoda, et al.
    • Journal Title

      Cancer Res 65

      Pages: 4939-4946

    • Related Report
      2005 Annual Research Report
  • [Journal Article] Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors : report of a case.2005

    • Author(s)
      Yuichi Ando, Takuya Tsunoda, et al.
    • Journal Title

      Surg Today. 35

      Pages: 157-160

    • NAID

      10014370499

    • Related Report
      2005 Annual Research Report
  • [Journal Article] Dendritic cell might be one of key factors for eliciting antitumor effect by chemo-immunotherapy in vivo.2005

    • Author(s)
      Hiroyuki Mushiake, Takuya Tsunoda, et al.
    • Journal Title

      Cancer Immunology Immunotherapy 54

      Pages: 120-128

    • Related Report
      2005 Annual Research Report
  • [Journal Article] Dendritic cell might be one of key factors for eliciting anti tumor effect by chemo-immunotherapy in vivo.2005

    • Author(s)
      Hiroyuki Mushiake et al.
    • Journal Title

      Cancer Immunology Immunotherapy 54

      Pages: 120-128

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Ring finger protein (RNF) 43 as a New Target for Cancer Immunotherapy.2004

    • Author(s)
      Uchida N, Tsunoda T, et al.
    • Journal Title

      Clinical Cancer Res 10

      Pages: 8577-8586

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Enhancement of Cytotoxic T Lymphocyte Responses in Patients with Gastrointestinal Malignancies following Vaccination with CEA peptide pulsed Dendritic cells.2004

    • Author(s)
      Matsuda K, Tsunoda T, et al.
    • Journal Title

      Cancer Immunol Immunother 53

      Pages: 609-616

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Ring finger protein (RNF) 43 as a New Target for Cancer Immunotherapy.2004

    • Author(s)
      Uchida N, Tsunoda T, et al.
    • Journal Title

      Clinical Cancer Res. 10

      Pages: 8577-8586

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Enhancement of Cytotoxic T Lymphocyte Responses in Patients with Gastrointestinal Malignancies following Vaccination with CEA peptide pulsed Dendritic cells2004

    • Author(s)
      Kenji Matsuda et al.
    • Journal Title

      Cancer Immunology Immunotherapy 53

      Pages: 609-616

    • Related Report
      2004 Annual Research Report

URL: 

Published: 2004-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi